Since SARS-CoV S protein binds to ACE2 and mediates viral entry, it is not surprising that S protein-specific antibodies would be effective in neutralizing SARS-CoV and could be used as therapeutics for active SARS-CoV infections. This evidence concerns the gene ACE2 and severe acute respiratory syndrome.